Octopamine

Octopamine

SCHEMBL1650462

NC[C@H](O)c1ccc(O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 4/20 1.00
HIF1A Q16665 3/20 1.00
NFKB1 P19838 3/20 1.00
TSHR P16473 2/20 1.00
HTR3A P46098 1/20 1.00
TDP1 Q9NUW8 6/20 0.95
KDM4E B2RXH2 5/20 0.95
APEX1 P27695 3/20 0.95
ALOX15 P16050 2/20 0.95
BLM P54132 6/20 0.59
MAPT P10636 4/20 0.59
RECQL P46063 3/20 0.59
LMNA P02545 3/20 0.59
HPGD P15428 2/20 0.59
MAPK1 P28482 2/20 0.59
ADRB2 P07550 2/20 0.59
ADRB1 P08588 2/20 0.59
ADRA2A P08913 2/20 0.59
ADRA2B P18089 2/20 0.59
ADRA2C P18825 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Octopamine SCHEMBL3489184 1.00 TAAR1 (1.00) TAAR1HIF1ANFKB1TSHRHTR3A
Octopamine SCHEMBL22605 1.00 TAAR1 (1.00) TAAR1HIF1ANFKB1TSHRHTR3A
Octopamine SCHEMBL4282037 0.98 TAAR1 (0.95) TAAR1HIF1ANFKB1TSHRHTR3A
Octopamine SCHEMBL30782000 0.98 TDP1 (1.00) TAAR1HIF1ANFKB1TSHRHTR3A
Octopamine SCHEMBL17688531 0.98 TAAR1 (0.95) TAAR1HIF1ANFKB1TSHRHTR3A
Octopamine SCHEMBL1168914 0.98 TDP1 (1.00) TAAR1HIF1ANFKB1TSHRHTR3A
Octopamine SCHEMBL5458985 0.98 TAAR1 (0.95) TAAR1HIF1ANFKB1TSHRHTR3A
Octopamine SCHEMBL9125963 0.95 TAAR1 (0.91) TAAR1HIF1ANFKB1TSHRHTR3A
Octopamine SCHEMBL8419660 0.91 TAAR1 (0.83) TAAR1HIF1ANFKB1TSHRHTR3A
Octopamine SCHEMBL25250966 0.89 TAAR1 (0.80) TAAR1HIF1ANFKB1TSHRHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112822948-A TAAR receptor agonists for the treatment of alopecia 应用生物学公司 2021-05-18 CN claimed
US-20210137854-A1 TAAR Receptor Agonists for the Treatment of Alopecia JUPITER WELLNESS INC. 2021-05-13 US claimed
US-20100143322-A1 USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE PLT PATENT & LICENCE TRADING LTD., C/O THE B-NET (GB) 2010-06-10 US claimed
EP-1917006-A2 USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE PLT Patent & Licence Trading Ltd. (GB) 2008-05-07 EP claimed
WO-2006136454-A2 USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE PLT PATENT & LICENCE TRADING LTD. (GB) 2006-12-28 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
US-5747462-A PLANT EXTRACT OF CACTACEAE CONTAINING AMINOETHYLPHENOLS, A DISACCHARIDE AND A MONSACCHARIDE LABORATORIO CHILE S.A. (CL) 1998-05-05 US claimed
CN-1127116-A New composition and subcompositions of same: process for obtaining them and their molecular identification, and their anti-inflammatory, analgesic, antipruritic and local antipyretic therapeutic effec CHILE LAB SA (CL) 1996-07-24 CN claimed
EP-0706797-A2 Compositions containing carbohydrates obtained from plants of the family cactacea LABORATORIO CHILE S.A. (CL) 1996-04-17 EP claimed
US-20260041652-A1 SYSTEM AND METHOD FOR PREVENTING ALOPECIA FOLLEA INT (US) 2026-02-12 US disclosed
EP-4686757-A1 INHIBITORS OF EXPRESSION AND/OR FUNCTION e-therapeutics PLC (GB) 2026-02-04 EP disclosed
WO-2025059259-A1 NEW PROCESS FOR PHENYLEPHRINE AND SALBUTAMOL AND RELATED COMPOUNDS VIA ASYMETRIC TRANSFER HYDROGENATION OF UNPROTECTED AMINO KETONES VIRGINIA COMMONWEALTH UNIVERSITY (US) 2025-03-20 WO disclosed
CN-115993416-B Method for detecting biogenic amine in fermentation product 浙江省疾病预防控制中心 2024-11-19 CN disclosed
CN-117756947-B High-throughput screening method for recombinant engineering protein and proteasome inhibitor 中南大学湘雅二医院 2024-09-06 CN disclosed
US-5128369-A Antiallergens, bronchodilator agents KYOWA HAKKO KOGYO CO., LTD. (JP) 1992-07-07 US disclosed
US-5120746-A Inhibit gastric acid secretion TOYAMA CHEMICAL CO., LTD. (JP) 1992-06-09 US disclosed
EP-0404197-A2 Arylalkylamine derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 1990-12-27 EP disclosed
US-4923882-A Novel amine derivatives, salts thereof and an anti-ulcer agent containing the same TOYAMA CHEMICAL CO., LTD. (JP) 1990-05-08 US disclosed
CN-87103323-A The method for preparing new Dopamine HCL, hydroxylase inhibitors 1988-02-03 CN disclosed
US-4643849-A ANTIULCER, ANTISECRETORY AGENTS TOYAMA CHEMICAL CO., LTD. (JP) 1987-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260041652-A1 SYSTEM AND METHOD FOR PREVENTING ALOPECIA DYRK4, DYRK2, STRA6 TAAR1 370/4885HIF1A 3522/4885NFKB1 1966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.